Compare NOTV & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOTV | NTHI |
|---|---|---|
| Founded | 1974 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 195.5M |
| IPO Year | 1997 | N/A |
| Metric | NOTV | NTHI |
|---|---|---|
| Price | $0.76 | $10.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 68.0K |
| Earning Date | 12-03-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $513,024,000.00 | $59,990.00 |
| Revenue This Year | $6.26 | N/A |
| Revenue Next Year | $45.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.54 | N/A |
| 52 Week Low | $0.66 | $3.20 |
| 52 Week High | $6.48 | $25.00 |
| Indicator | NOTV | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 35.16 | 58.54 |
| Support Level | $0.79 | $8.63 |
| Resistance Level | $0.86 | $9.75 |
| Average True Range (ATR) | 0.07 | 0.88 |
| MACD | 0.01 | 0.23 |
| Stochastic Oscillator | 3.93 | 95.59 |
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).